A Comprehensive Review of Contemporary Literature for Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer and Their Toxicity.
Chung-Shien LeeSandhya SharmaEmily MiaoCheryl MensahKevin SullivanNagashree SeetharamuPublished in: Lung Cancer (Auckland, N.Z.) (2020)
Mutations in the epidermal growth factor receptor (EGFR) are common amongst those with non-small cell lung cancer and represent a major factor in treatment decisions, most notably in the advanced stages. Small molecule tyrosine kinase inhibitors (TKIs) that target the EGFR, such as erlotinib, gefitinib, icotinib, afatinib, dacomitinib and osimertinib, have all shown to be effective in this setting. Osimertinib, a third-generation EGFR TKI, is a favorable option, but almost all patients develop resistance at some time point. There are no effective treatment options for patients who progress on osimertinib, but ongoing trials will hopefully address this unmet need. The aim of this review is to provide a comprehensive review of the data with EGFR TKIs, management of the toxicities and the ongoing trials with this class of agents.
Keyphrases
- epidermal growth factor receptor
- advanced non small cell lung cancer
- tyrosine kinase
- small molecule
- end stage renal disease
- chronic kidney disease
- small cell lung cancer
- systematic review
- ejection fraction
- chronic myeloid leukemia
- prognostic factors
- electronic health record
- machine learning
- combination therapy
- protein protein